Scolaris Content Display Scolaris Content Display

Contenido relacionado

Ir a:

Revisiones y protocolos relacionados

Topics

Temas

Study flow diagram.
Figuras y tablas -
Figure 1

Study flow diagram.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Table 1. Type of intervention: intravenous tocilizumab treatment versus standard treatment. Type of studies: randomised controlled trials

Outcomes

Measure

Relative effect

Number of participants
(studies)

Quality of evidence
(GRADEa)

Comments

Change in TED as defined by investigators

Measured in CAS/EUGOGO/NOSPECS/VISA classification at 12 months (range 6–18 months) post treatment

—

—

—

—

Change in proptosis

Measured in millimetres at 12 months (range 6–18 months) post treatment

—

—

—

—

Change in extraocular motility

Measured in degrees at 12 months (range 6–18 months) post treatment

—

—

—

—

Number of relapses

Per participant at 12 months (range 6–18 months) post treatment

—

—

—

—

Development of optic neuropathy

As defined by the trial investigators at 12 months (range 6–18 months) post treatment

—

—

—

—

Change in quality‐of‐life score

GO‐QOL score or EQ‐5D score at 12 months (range 6–18 months) post treatment

—

—

—

MCID = 6 points

Adverse effects

Any adverse effect that is reported at 12 months (range 6–18 months) post treatment

—

—

—

—

aThe GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the quantity of specific interest. Certainty of a body of evidence involves consideration of within‐study risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias.
CAS: Clinical Activity Score; EQ‐5D: European Quality of life questionnaire; EUGOGO: European Group On Graves' Orbitopathy; GO‐QOL: Graves' Orbitopathy Quality of Life questionnaire; MCID: minimal clinically important difference; NOSPECS: No symptoms or signs, Only signs, Soft tissue involvement, Proptosis, Extraocular muscle involvement, Corneal involvement and Sight loss. It is graded as 0, a, b or c; TED: thyroid eye disease; VISA: Vision, Inflammation, Strabismus, and Appearance classification.
We planned to express the treatment effect for each continuous outcome as a mean difference with 95% confidence interval (CI). Where continuous outcomes were measured using different scales, we planned to express the treatment effect as a standardised mean difference with 95% CI.

Figuras y tablas -
Table 1. Type of intervention: intravenous tocilizumab treatment versus standard treatment. Type of studies: randomised controlled trials
Ir a la tabla de la revisión
Table 2. Type of intervention: intravenous tocilizumab treatment versus placebo. Type of studies: randomised controlled trials

Outcomes

Measure

Relative
effect

Number of participants
(studies)

Quality of evidence
(GRADEa)

Comments

Change in TED as defined by investigators

Measured in CAS/EUGOGO/NOSPECS/VISA classification at 12 months (range 6–18 months) post treatment

—

—

—

—

Change in proptosis

Measured in millimetres at 12 months (range 6–18 months) post treatment

—

—

—

—

Change in extraocular motility

Measured in degrees at 12 months (range 6–18 months) post treatment

—

—

—

—

Number of relapses

Per participant at 12 months (range 6–18 months) post treatment

—

—

—

—

Development of optic neuropathy

As defined by the trial investigators at 12 months (range 6–18 months) post treatment

—

—

—

—

Change in quality‐of‐life score

GO‐QOL score or EQ‐5D score at 12 months (range 6–18 months) post treatment

—

—

—

MCID = 6 points

Adverse effects

Any adverse effect that is reported at 12 months (range 6–18 months) post treatment

—

—

—

—

aThe GRADE approach defines the quality of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the quantity of specific interest. Certainty of a body of evidence involves consideration of within‐study risk of bias (methodological quality), directness of evidence, heterogeneity, precision of effect estimates and risk of publication bias.
CAS: Clinical Activity Score; EQ‐5D: European Quality of life questionnaire; EUGOGO: European Group On Graves' Orbitopathy; GO‐QOL: Graves' Orbitopathy Quality of Life questionnaire; MCID: minimal clinically important difference; NOSPECS: No symptoms or signs, Only signs, Soft tissue involvement, Proptosis, Extraocular muscle involvement, Corneal involvement and Sight loss. It is graded as 0, a, b or c; TED: thyroid eye disease; VISA: Vision, Inflammation, Strabismus, and Appearance classification.
We planned to express the treatment effect for each continuous outcome as a mean difference with 95% confidence interval (CI). Where continuous outcomes were measured using different scales, we planned to express the treatment effect as a standardised mean difference with 95% CI.

Figuras y tablas -
Table 2. Type of intervention: intravenous tocilizumab treatment versus placebo. Type of studies: randomised controlled trials
Ir a la tabla de la revisión